Expression of Bile Duct Transcription Factor HNF1β Predicts Early Tumor Recurrence and is a Stage-independent Prognostic Factor in Hepatocellular Carcinoma

Overview

Journal J Gastrointest Surg

Specialty Gastroenterology

Date 2014 Jul 24

PMID 25052070

Citations 8

Authors

Ray-Hwang Yuan

Hong-Shiee Lai

Hey-Chi Hsu

Po-Lin Lai

Yung-Ming Jeng

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocellular carcinoma (HCC) frequently exhibits biliary differentiation, which is typically overlooked. Hepatocyte nuclear factor 1β (HNF1β), a bile duct-specific transcription factor expressed in bile ducts but not in the normal hepatocytes, is also expressed in HCC.

Materials And Methods: The expression of HNF1β and the biliary differentiation marker cytokeratin 19 (CK19) were retrospectively evaluated using immunohistochemistry in 159 surgically resected primary HCCs.

Results: A significant correlation was observed between HNF1β protein expression and younger age (p = 0.0293), high serum α-fetoprotein levels (p = 6 × 10(-4)), and high tumor grade (p = 0.0255). However, HNF1β expression exhibited no correlation with tumor stage. Patients with HCCs and HNF1β expression were more likely to exhibit early tumor recurrence (ETR; p = 0.0048) and a lower 5-year survival rate (p = 0.0001). A multivariate analysis indicated HNF1β expression as an independent prognostic factor in HCC (p = 0.0048). A combinatorial analysis revealed additive adverse effects of HNF1β when concomitant with CK19 expression and p53 mutation. Furthermore, HNF1β expression can predict poor prognosis in patients with ETR.

Conclusion: Our results indicated that HNF1β expression is a crucial predictor of poor prognosis in HCC and is independent of tumor stage. Moreover, concomitant HNF1β and CK19 expressions exhibited additive adverse effects in HCC, confirming that HCC with biliary differentiation has a poor prognosis.

Citing Articles

Tumor-matrix interaction induces phenotypic switching in liver cancer cells.

Yuan R, Hsu C, Jhuang Y, Liu Y, Hsieh T, Jeng Y Hepatol Int. 2022; 16(3):562-576.

PMID: 35525880 DOI: 10.1007/s12072-022-10315-w.

Hepatocellular Carcinoma Differentiation: Research Progress in Mechanism and Treatment.

Song J, Zhou H, Gu D, Xu Y Front Oncol. 2022; 11:790358.

PMID: 35096588 PMC: 8790246. DOI: 10.3389/fonc.2021.790358.

Circular RNAs: Functions and Prospects in Glioma.

Hao Z, Hu S, Liu Z, Song W, Zhao Y, Li M J Mol Neurosci. 2018; 67(1):72-81.

PMID: 30460608 DOI: 10.1007/s12031-018-1211-2.

Increased Trimethylation of histone H3K36 associates with biliary differentiation and predicts poor prognosis in resectable hepatocellular carcinoma.

Lien H, Jeng Y, Jhuang Y, Yuan R PLoS One. 2018; 13(10):e0206261.

PMID: 30356299 PMC: 6200274. DOI: 10.1371/journal.pone.0206261.

Hepatocyte nuclear factor-1beta enhances the stemness of hepatocellular carcinoma cells through activation of the Notch pathway.

Zhu J, Jiang L, Jiang J, Yang X, Li X, Zeng J Sci Rep. 2017; 7(1):4793.

PMID: 28684878 PMC: 5500528. DOI: 10.1038/s41598-017-04116-7.

References

Yuan R, Jeng Y, Chen H, Lai P, Pan H, Hsieh F . Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol. 2006; 209(4):549-58. DOI: 10.1002/path.2011. View

Ding S, Li Y, Tan Y, Jiang M, Tian B, Liu Y . From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics. 2003; 3(1):73-81. DOI: 10.1074/mcp.M300094-MCP200. View

EDMONDSON H, STEINER P . Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954; 7(3):462-503. DOI: 10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e. View

Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H . Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci. 2003; 94(10):851-7. PMC: 11160230. DOI: 10.1111/j.1349-7006.2003.tb01366.x. View

Buchner A, Castro M, Hennig A, Popp T, Assmann G, Stief C . Downregulation of HNF-1B in renal cell carcinoma is associated with tumor progression and poor prognosis. Urology. 2010; 76(2):507.e6-11. DOI: 10.1016/j.urology.2010.03.042. View

Shim J, Lee H, Han S, Kang H, Yu E, Lee S . Hepatocyte nuclear factor 1β is a novel prognostic marker independent of the Milan criteria in transplantable hepatocellular carcinoma: a retrospective analysis based on tissue microarrays. Liver Transpl. 2012; 19(3):336-45. DOI: 10.1002/lt.23584. View

Poon R, Fan S, Ng I, Lo C, Liu C, Wong J . Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000; 89(3):500-7. View

Lai Y, Thung S, Gerber M, Chen M, Schaffner F . Expression of cytokeratins in normal and diseased livers and in primary liver carcinomas. Arch Pathol Lab Med. 1989; 113(2):134-8. View

Yuan R, Chang K, Chen Y, Hsu H, Lee P, Lai P . S100P expression is a novel prognostic factor in hepatocellular carcinoma and predicts survival in patients with high tumor stage or early recurrent tumors. PLoS One. 2013; 8(6):e65501. PMC: 3681902. DOI: 10.1371/journal.pone.0065501. View

10.

BLUMENFELD M, Maury M, Chouard T, Yaniv M, Condamine H . Hepatic nuclear factor 1 (HNF1) shows a wider distribution than products of its known target genes in developing mouse. Development. 1991; 113(2):589-99. DOI: 10.1242/dev.113.2.589. View

11.

Elliott K, Zeggini E, McCarthy M, Gudmundsson J, Sulem P, Stacey S . Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies. PLoS One. 2010; 5(5):e10858. PMC: 2878330. DOI: 10.1371/journal.pone.0010858. View

12.

Peng S, Chen W, Lai P, Jeng Y, Sheu J, Hsu H . High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer. 2004; 112(1):44-50. DOI: 10.1002/ijc.20279. View

13.

Pan H, Ou Y, Peng S, Liu S, Lai P, Lee P . Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 2003; 98(1):119-27. DOI: 10.1002/cncr.11487. View

14.

Peng S, Ou Y, Chen W, Li H, Liu S, Pan H . Aberrant expressions of annexin A10 short isoform, osteopontin and alpha-fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma. Int J Oncol. 2005; 26(4):1053-61. View

15.

Yuan R, Jeng Y, Chen H, Hsieh F, Yang C, Lee P . Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-associated protein expression with low-stage hepatocellular carcinoma, beta-catenin mutation, and favorable.... Clin Cancer Res. 2005; 11(7):2568-75. DOI: 10.1158/1078-0432.CCR-04-2039. View

16.

Shen H, Fridley B, Song H, Lawrenson K, Cunningham J, Ramus S . Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun. 2013; 4:1628. PMC: 3848248. DOI: 10.1038/ncomms2629. View

17.

Hsu H, Peng S, Lai P, Chu J, Lee P . Mutations of p53 gene in hepatocellular-carcinoma (hcc) correlate with tumor progression and patient prognosis - a study of 138 patients with unifocal hcc. Int J Oncol. 2011; 4(6):1341-7. DOI: 10.3892/ijo.4.6.1341. View

18.

Coffinier C, Gresh L, Fiette L, Tronche F, Schutz G, Babinet C . Bile system morphogenesis defects and liver dysfunction upon targeted deletion of HNF1beta. Development. 2002; 129(8):1829-38. DOI: 10.1242/dev.129.8.1829. View

19.

Lee J, Lee J, Kim J, Kim J, Chung H, Kim Y . Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers. World J Gastroenterol. 2012; 18(34):4751-7. PMC: 3442214. DOI: 10.3748/wjg.v18.i34.4751. View

20.

Zhang F, Chen X, Zhang W, Dong H, Xiang S, Zhang W . Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology. 2008; 52(2):224-32. DOI: 10.1111/j.1365-2559.2007.02929.x. View